Gastrointestinal Cancer News

The American Society for Radiation Oncology will hold its annual meeting from Sept. 25 to 28 in Boston.

Adenoma detection rates in colonoscopy-based and fecal immunochemical testing-based colorectal cancer screening programs appeared positively and significantly correlated, according to a post-hoc analysis of the Spanish COLONPREV study.

Having non-hepatitis C virus cirrhosis and diabetes puts patients at a higher risk for developing hepatocellular carcinoma, according to research recently published in The American Journal of Gastroenterology.

Sexual activity and function appeared no different in cancer survivors than in cancer-free adults aged 50 years or older, according to results of a population-based study.

The approval and availability of new immunotherapy treatments sparked the need for dissemination of these therapies to patients throughout the cancer care community.

A phase 2 trial designed to evaluate ENMD-2076 for the treatment of fibrolamellar carcinoma met its stage 1 endpoint of objective response for nonfutility based on prespecified interim analysis criteria, according to the agent’s manufacturer.

Healio.com/HemOnc has launched In the Journals Plus, a new feature that will provide busy physicians with summaries of the top articles from leading journals in hematology and oncology.

Codrituzumab was non-effective in patients who had already failed treatment for hepatocellular carcinoma, according to a phase 2 study published in the Journal of Hepatology.

CMS has released an updated Evidence of Coverage notice confirming that Medicare Advantage plans must cover Cologuard every 3 years without patient coinsurance, copayments or deductibles, according to a press release from the manufacturer.

Life-preserving treatments once frequently threatened the fertility of patients with cancer.